JP2016514135A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514135A5
JP2016514135A5 JP2016501388A JP2016501388A JP2016514135A5 JP 2016514135 A5 JP2016514135 A5 JP 2016514135A5 JP 2016501388 A JP2016501388 A JP 2016501388A JP 2016501388 A JP2016501388 A JP 2016501388A JP 2016514135 A5 JP2016514135 A5 JP 2016514135A5
Authority
JP
Japan
Prior art keywords
cancer
hydrochloride
tumor
cell
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016501388A
Other languages
English (en)
Japanese (ja)
Other versions
JP6488276B2 (ja
JP2016514135A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/023934 external-priority patent/WO2014159500A1/en
Publication of JP2016514135A publication Critical patent/JP2016514135A/ja
Publication of JP2016514135A5 publication Critical patent/JP2016514135A5/ja
Application granted granted Critical
Publication of JP6488276B2 publication Critical patent/JP6488276B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016501388A 2013-03-14 2014-03-12 天然化合物及び/又は食事を用いる癌の調節 Expired - Fee Related JP6488276B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784386P 2013-03-14 2013-03-14
US61/784,386 2013-03-14
PCT/US2014/023934 WO2014159500A1 (en) 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018093204A Division JP2018162248A (ja) 2013-03-14 2018-05-14 天然化合物及び/又は食事を用いる癌の調節

Publications (3)

Publication Number Publication Date
JP2016514135A JP2016514135A (ja) 2016-05-19
JP2016514135A5 true JP2016514135A5 (enExample) 2017-04-13
JP6488276B2 JP6488276B2 (ja) 2019-03-20

Family

ID=51625178

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016501388A Expired - Fee Related JP6488276B2 (ja) 2013-03-14 2014-03-12 天然化合物及び/又は食事を用いる癌の調節
JP2018093204A Pending JP2018162248A (ja) 2013-03-14 2018-05-14 天然化合物及び/又は食事を用いる癌の調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018093204A Pending JP2018162248A (ja) 2013-03-14 2018-05-14 天然化合物及び/又は食事を用いる癌の調節

Country Status (9)

Country Link
US (2) US20160038456A1 (enExample)
EP (1) EP2968260B1 (enExample)
JP (2) JP6488276B2 (enExample)
CN (2) CN105377252A (enExample)
AU (3) AU2014240467B2 (enExample)
BR (1) BR112015023190A2 (enExample)
CA (1) CA2912518A1 (enExample)
IN (1) IN2015DE09621A (enExample)
WO (1) WO2014159500A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
JP2018518513A (ja) * 2015-06-26 2018-07-12 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 天然の化合物および/または規定食を用いた炎症の治療方法
CN107921133A (zh) 2015-09-04 2018-04-17 国立大学法人大阪大学 癌症的饮食疗法开发
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN108192866B (zh) * 2018-03-07 2021-05-11 郑州大学第一附属医院 Sfn联合il-15和il-21制备记忆性t细胞的方法及应用
KR102174166B1 (ko) * 2018-12-13 2020-11-04 영남대학교 산학협력단 호모해링토닌을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
CN110420178B (zh) * 2019-09-11 2022-08-05 长江师范学院 一种胭脂萝卜硫苷水凝胶的制备方法
EP3861992B1 (en) * 2020-02-07 2023-09-06 CannaFamily a.s. Combination therapy comprising plant derived compounds and antineoplastic compounds for treatment of hematological malignancies
AU2020468941A1 (en) * 2020-09-23 2023-03-23 Aminovita S.L. Metabolic cancer therapy
TW202339712A (zh) * 2022-01-24 2023-10-16 國立大學法人大阪大學 用於治療癌症之組合物
CN118259005B (zh) * 2023-12-08 2026-07-17 浙江省肿瘤医院 一种放射性碘难治性分化型甲状腺癌的生物标记物及应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725895B1 (en) * 1995-09-15 2000-10-10 Hopkins J School Of Medicine Method of preparing food product from cruciferous seeds
US6242018B1 (en) * 1997-04-11 2001-06-05 Johns Hopkins School Of Medicine Cancer Chemoprotective food products
JPH1149793A (ja) * 1997-08-08 1999-02-23 Momoya:Kk 野菜由来の抗腫瘍性物質
CN1141092C (zh) * 2001-01-19 2004-03-10 郭兴华 一种防治骨质疏松、癌症和降血脂组合物及其应用
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US20090143433A1 (en) 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
JP2007153834A (ja) * 2005-12-07 2007-06-21 Univ Kansai カイワレ大根由来の不凍活性を有する抽出物、その製造方法、ならびにその用途
JP2011500680A (ja) 2007-10-16 2011-01-06 ジョンズ・ホプキンス・ユニヴァーシティ 放射線傷害から皮膚を保護する方法
US20090252758A1 (en) * 2008-04-07 2009-10-08 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
AR084174A1 (es) 2010-12-21 2013-04-24 Lilly Co Eli Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
DE102011008016A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
DE102011008017A1 (de) 2011-01-06 2012-07-12 Johannes F. Coy Erfrischungsgetränk
WO2012113415A1 (en) * 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
CA2831403A1 (en) * 2011-05-19 2012-11-22 Glax L.L.C. Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
GB201210699D0 (en) 2012-06-15 2012-08-01 Vitaflo Ltd Nutritional food
RU2666953C2 (ru) 2012-07-05 2018-09-13 Нутрамакс Лабораториз, Инк. Композиции, содержащие сульфорафан или предшественник сульфорафана и экстракт или порошок молочного чертополоха
US20140275235A1 (en) 2013-03-15 2014-09-18 Loic Pierre Deleyrolle Treatment of Proliferative Disorders
EP2968990A4 (en) 2013-03-15 2016-08-24 Nutramax Lab Inc COMPOSITIONS COMPRISING SULFORAPHANE OR SULFORAPHANE PRECURSOR AND PHYTOSTEROL OR PHYTOSTANOL
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
CN105431159B (zh) 2013-05-14 2020-12-01 马斯公司 关节护理组合物
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
WO2015034812A2 (en) 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
JP2018518513A (ja) 2015-06-26 2018-07-12 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 天然の化合物および/または規定食を用いた炎症の治療方法

Similar Documents

Publication Publication Date Title
Kawish et al. Nanoparticle‐based drug delivery platform for simultaneous administration of phytochemicals and chemotherapeutics: emerging trends in cancer management
US20210338701A1 (en) Dna hypomethylating agents for cancer therapy
JP6685875B2 (ja) 治療薬の組み合わせおよび投与の様式ならびに併用療法
JP6488276B2 (ja) 天然化合物及び/又は食事を用いる癌の調節
JP2016535756A5 (enExample)
RU2012140447A (ru) Антиангиогенная терапия для лечения рака яичника
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
NZ588668A (en) Uses of helicin and other glucopyranosyloxy benzaldehydes in the treatment of cancer
Wang et al. A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)
WO2015180600A1 (zh) 一种具有抗肿瘤增效减毒效果的药用溶液及包含其的药用组合物
JP2022523672A (ja) がんを治療するための金属キレート化剤併用療法
JP2020523384A (ja) 抗cd25 adcを投与するための投与レジメ
Minami et al. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status
Kusagaya et al. Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a randomized, phase-II study
Manatunga Effective delivery of hydrophobic drugs to breast (MCF-7) and Liver (HepG2) cancer cells: a detailed investigation using cytotoxicity assays, fluorescence imaging and flow cytometry
US20150272967A1 (en) Extremely high loading dose
Yokoi et al. A phase II study of tailored-dose S-1 plus carboplatin followed by maintenance S-1 for advanced squamous cell lung cancer: OSAKA-LCSG 1102
JP2021534091A5 (enExample)
Cortesi et al. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15
Abdul Halim et al. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region
Francini et al. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival
Liu et al. Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma
Bhise Chronic myeloid leukemia with variant chromosomal translocations: results of treatment with imatinib mesylate
Yerrapragada Elucidating the release and biological effects of extracellular platinum adduct-containing DNA.
JP2024531765A (ja) がん治療のための三剤療法